Par Drugs Q2 FY26 Results: PAT Rs 412.96 lakh, Revenue Rs 2,865.89 lakh

Revenue declinedResults View source PDF Explain this filing

PAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.3%Reaction day

₹99.25

prior close

₹96.50

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-5.2% vs market

Pharmaceuticals peers, median of 157sector+0.0%-5.3% vs sector

On the reaction day the stock moved 5.2 pts less than Nifty Microcap 250 and 5.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.5

10m

+1.5

15m

+1.5

30m

+0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.3-0.1-5.2+0.0-5.3

Next day

-5.3+0.5-5.8-0.1-5.2

-4.8-0.3-4.5-0.9-3.9

-6.3-0.5-5.8-1.3-5.0

-7.3-0.8-6.5-1.6-5.7

-7.2-2.3-4.9-2.3-4.9

-9.4-2.8-6.6-2.9-6.5

15d

-2.8-4.9+2.1-3.6+0.8

+1.8-4.7+6.5-4.4+6.1

-6.8-7.7+0.9-5.6-1.2

-0.3-7.8+7.6-10.7+10.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved unaudited Q2 and H1 FY26 results on 13 Nov 2025. Q2 revenue from operations Rs 2,865.89 lakh vs Rs 3,465.69 lakh YoY, down about 17 percent. Q2 PAT Rs 412.96 lakh vs Rs 859.58 lakh YoY, down about 52 percent. H1 FY26 revenue Rs 5,702.22 lakh, PAT Rs 745.77 lakh vs Rs 1,112.89 lakh YoY. Q2 EPS Rs 3.36 vs Rs 6.99. No exceptional items. Auditor gave an unmodified limited review.

Likely market impact

Sharp YoY profit decline despite positive earnings. Watch for margin compression and demand recovery in upcoming quarters.